x

Posted 16 February, 2022

JOHNSON & JOHNSON appointed new CEO

CEO Change detected for ticker NYSE:JNJ in a 8-K filed on 16 February, 2022.


  Johnson & Johnson (the "Company") announced on February 15, 2022, that Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, has been appointed to its Board of Directors (the "Board"), effective immediately.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of JOHNSON & JOHNSON
Health Care/Life Sciences • Pharmaceuticals
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Market Cap
$385B
View Company Details
JOHNSON & JOHNSON by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Johnson & Johnson (the "Company") announced on February 15, 2022, that Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, has been appointed to its Board of Directors (the "Board"), effective immediately. Mr. Adamczyk will serve as a member of the Board's Audit Committee and Compensation & Benefits Committee, effective as of April 28, 2022. As a non-employee Director of the Company, Mr. Adamczyk will receive compensation as described in the "Director Compensation" section of the Company's 2022 Proxy Statement.


The Company's press release announcing the appointment is attached to this Report as Exhibit 99.1.